Synopsis
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDA Orange Book
0
Europe
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1-vinyl-2-pyrrolidone
2. N- Vinyl Pyrrolidone
3. N-vinyl-2-pyrrolidinone
4. N-vinylpyrrolidone
1. 88-12-0
2. 1-vinylpyrrolidin-2-one
3. N-vinylpyrrolidone
4. 1-vinyl-2-pyrrolidone
5. N-vinyl-2-pyrrolidinone
6. Polyvinylpyrrolidone
7. Vinylpyrrolidone
8. 9003-39-8
9. 1-vinyl-2-pyrrolidinone
10. Povidone
11. 2-pyrrolidinone, 1-ethenyl-
12. 1-ethenylpyrrolidin-2-one
13. N-vinylpyrrolidinone
14. Polyvidone
15. 1-vinylpyrrolidone
16. Vinylbutyrolactam
17. Plasdone
18. Vinylpyrrolidinone
19. V-pyrol
20. Luviskol
21. 1-vinylpyrrolidinone
22. Vinyl-2-pyrrolidone
23. 25249-54-1
24. Polyclar At
25. N-vinyl Pyrrolidone
26. 1-ethenyl-2-pyrrolidinone
27. N-vinylpyrrolidone-2
28. 2-pyrrolidinone, 1-vinyl-
29. Poly(n-vinylpyrrolidone)
30. 1-vinyl-2-pyrrolidinone, Monomer
31. Poly(1-vinyl-2-pyrrolidone)
32. Pvp 40
33. Pvp
34. Nsc 10222
35. Mpk 90
36. 143 Rp
37. At 717
38. 1-vinyl-pyrrolidin-2-one
39. K 15
40. K 90
41. Pvp-40
42. Dtxsid2021440
43. Chebi:82551
44. Poly[1-(2-oxo-1-pyrrolidinyl)-1,2-ethanediyl]
45. Mfcd00003197
46. Nsc-10222
47. 2-pyrrolidinone, 1-ethenyl-, Trimer
48. 2-pyrrolidinone, Polymers
49. 76h9g81541
50. Dsstox_cid_1440
51. Dsstox_rid_76160
52. Dsstox_gsid_21440
53. Wln: /t5nvtj Ay*1*/
54. Mfcd01076626
55. Cas-88-12-0
56. Polyvinylpyrrolidine
57. 109412-11-5
58. K 25
59. K 115
60. Hsdb 7231
61. Einecs 201-800-4
62. Polyvinylpyrrolidone K 90
63. Polyvinylpyrrolidone K-30
64. 2-pyrrolidinone, Polymers, Compd. With Aluminum Acetate
65. Brn 0110513
66. Ccris 8581
67. Povidonepvp
68. Vinyl Pyrrolidone
69. Polyvinylpyrrolidon
70. Poly[1-(2-oxo-1-pyrrolidinyl)-1, .alpha.-hydro-.omega.-[[4-(iodo-131i)phenyl]methyl]-
71. Unii-76h9g81541
72. N-vinyl-pyrrolidone
73. N -vinylpyrrolidinone
74. 1-vinyl-2-pyrrolidon
75. Povidone Monomer
76. Vinylbutylolactam
77. N-vinylpyrrolidin-2-one
78. N-vinyl Pyrrolidin-2-one
79. N-vinyl-pyrrolidin-2-one
80. Pvp K3o
81. Crospovidone ~40,000
82. Ec 201-800-4
83. Poly (n-vinyl Pyrrolidone)
84. Schembl10869
85. Wln: T5nvtj A1u1
86. Pvp K15
87. Pvp K30
88. Pvp-k30
89. Polyvinylpyrrolidone Pvp K30
90. Povidone Monomer [mi]
91. Vinyl Pyrrolidone (vp)
92. Poly(1-vinylpyrrolidin-2-one)
93. Chembl1878943
94. Pvp - K-30 (pharm Grade)
95. Polyvinylpyrrolidone, Cross Linked
96. N-vinyl Pyrrolidone [inci]
97. 1-vinyl-2-pyrrolidone(stabilized With 200ppm Ammonium Hydroxide)
98. Nsc10222
99. Zinc3590964
100. Polyvinylpyrrolidone, M.w. 8,000
101. Tox21_202462
102. Tox21_300073
103. Nsc114022
104. Nsc142693
105. Nsc683040
106. N-vinyl-2-pyrrolidone, Optical Grade
107. Polyvinylpyrrolidone (mw ~40,000)
108. Polyvinylpyrrolidone, M.w. 10.000
109. Polyvinylpyrrolidone, M.w. 40.000
110. Polyvinylpyrrolidone, M.w. 58,000
111. Akos000119985
112. N-vinyl-2-pyrrolidone [iarc]
113. At18510
114. Cs-w020981
115. Fg-0420
116. Nsc-114022
117. Nsc-142693
118. Nsc-683040
119. Polyvinylpyrrolidone, M.w. 360.000
120. Ncgc00166252-01
121. Ncgc00166252-02
122. Ncgc00166252-03
123. Ncgc00254200-01
124. Ncgc00260011-01
125. Polyvinylpyrrolidone, M.w. 1,300,000
126. 2-pyrrolidinone, 1-ethenyl-[hsdb]
127. Ft-0608329
128. Ft-0645144
129. Ft-0655284
130. V0026
131. C19548
132. A817742
133. A843417
134. Poly(n-vinyl-2-pyrrolidone) (low M.wt.)
135. Q420628
136. Sr-01000944531
137. J-015891
138. Sr-01000944531-1
139. W-100417
140. 1-vinyl-2-pyrrolidinone, Saj First Grade, >=99.0%
141. F8881-5579
142. 3-chloro-5,6-difluoro-1-benzothiophene-2-carbonylchloride
143. 1-vinyl-2-pyrrolidinone, Contains Sodium Hydroxide As Inhibitor, >=99%
144. 1-vinyl-2-pyrrolidinone, Pharmaceutical Secondary Standard; Certified Reference Material
145. 1-vinyl-2-pyrrolidone (stabilized With N,n'-di-sec-butyl-p-phenylenediamine)
| Molecular Weight | 111.14 g/mol |
|---|---|
| Molecular Formula | C6H9NO |
| XLogP3 | 0.4 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 1 |
| Rotatable Bond Count | 1 |
| Exact Mass | 111.068413911 g/mol |
| Monoisotopic Mass | 111.068413911 g/mol |
| Topological Polar Surface Area | 20.3 Ų |
| Heavy Atom Count | 8 |
| Formal Charge | 0 |
| Complexity | 120 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Pharmaceutic Aids; Plasma Substitutes
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
CLINICAL INDICATIONS: ...FOR ALL PATHOLOGICAL CONDITIONS WHERE THERE IS DECR IN MASS OF LIQ BLOOD: SHOCK STATE... HEMORRHAGE...SERIOUS BURNS. ANTHREPSIA & NEURO-TOXICOSES OF INFANTS.
Lefaux, R. Practical Toxicology of Plastics. Cleveland: CRC Press Inc., 1968., p. 292
...HAS BEEN USED IN A...SERIES OF PATIENTS TO REPLACE THE AQ HUMOR AFTER EXTRACTION OF CATARACTS, CORNEAL TRANSPLANTS, & ANTIGLAUCOMA OPERATIONS.
Grant, W.M. Toxicology of the Eye. 3rd ed. Springfield, IL: Charles C. Thomas Publisher, 1986., p. 758
1. 1= PRACTICALLY NONTOXIC: PROBABLE ORAL LETHAL DOSE (HUMAN) ABOVE 15 G/KG, MORE THAN 1 QUART (2.2 LB) FOR 70 KG PERSON (150 LB).
Gosselin, R.E., H.C. Hodge, R.P. Smith, and M.N. Gleason. Clinical Toxicology of Commercial Products. 4th ed. Baltimore: Williams and Wilkins, 1976., p. II-245
When in complex with iodine, indicated for inducing antisepsis for prevention of infection in minor cuts, scrapes, and burns.
When in complex with iodine, indicated for inducing antisepsis for prevention of infection in minor cuts, scrapes, and burns.
Povidone itself has no microbicidal activity. [DB06812] exhibits rapid, potent, broad-spectrum antimicrobial properties. The clinical effectiveness of povidon-iodine on wound healing remains somewhat controversial; in few clinical studies investigating the effects of povidone-iodine on wound healing, topical administration of the complex was associated with no significant infections, but slower healing and mild to moderate discomfort on application.
Povidone itself has no microbicidal activity. [Povidone-iodine] exhibits rapid, potent, broad-spectrum antimicrobial properties. The clinical effectiveness of povidon-iodine on wound healing remains somewhat controversial; in few clinical studies investigating the effects of povidone-iodine on wound healing, topical administration of the complex was associated with no significant infections, but slower healing and mild to moderate discomfort on application.
Biocompatible Materials
Synthetic or natural materials, other than DRUGS, that are used to replace or repair any body TISSUES or bodily function. (See all compounds classified as Biocompatible Materials.)
Absorption
This pharmacokinetic data does not apply to povidone.
Route of Elimination
This pharmacokinetic data does not apply to povidone.
Volume of Distribution
This pharmacokinetic data does not apply to povidone.
Clearance
This pharmacokinetic data does not apply to povidone.
Absorption
This pharmacokinetic data does not apply to povidone.
Route of Elimination
This pharmacokinetic data does not apply to povidone.
Volume of Distribution
This pharmacokinetic data does not apply to povidone.
Clearance
This pharmacokinetic data does not apply to povidone.
WHEN GIVEN PARENTERALLY, UNEXCRETED PARTICLES ARE PHAGOCYTIZED BY CELLS OF RETICULOENDOTHELIAL SYSTEM & DEPOSITED IN STORAGE SITES IN LIVER, SPLEEN, LUNG, BONE MARROW...
Gosselin, R.E., H.C. Hodge, R.P. Smith, and M.N. Gleason. Clinical Toxicology of Commercial Products. 4th ed. Baltimore: Williams and Wilkins, 1976., p. II-245
...30-40% OF SUBTOSAN PASSES INTO THE URINE IN THE FIRST 24 HR & ABOUT 50% IN THE FIRST 2 DAYS. ...SMALLEST MOLECULES ARE...FIRST & MOST RAPIDLY EXCRETED. IT TAKES 10 DAYS AFTER PERFUSION FOR 80% OF AMT INJECTED TO BE ELIMINATED.
Lefaux, R. Practical Toxicology of Plastics. Cleveland: CRC Press Inc., 1968., p. 292
INTERMEDIATE MOLECULR WT PARTICLES MAY BE SLOWLY EXCRETED OVER SEVERAL MONTHS TO A YR.
Gosselin, R.E., H.C. Hodge, R.P. Smith, and M.N. Gleason. Clinical Toxicology of Commercial Products. 4th ed. Baltimore: Williams and Wilkins, 1976., p. II-245
IN GROUPS OF RATS FED DIETS CONTAINING 1 & 10% PVP (MOLECULAR WEIGHT 38,000) FOR 2 YEARS...THERE WAS NO EVIDENCE THAT PVP WAS ABSORBED FROM THE INTESTINAL TRACT.
IARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work). Available at: https://monographs.iarc.fr/ENG/Classification/index.php, p. V19 471
For more Absorption, Distribution and Excretion (Complete) data for POLYVINYLPYRROLIDONE (6 total), please visit the HSDB record page.
This pharmacokinetic data does not apply to povidone.
This pharmacokinetic data does not apply to povidone.
PVP LABELLED WITH (14)C OR (131)I WAS NOT METABOLIZED TO ANY SIGNIFICANT DEGREE BY RATS, RABBITS OR DOGS FOLLOWING ITS IV INJECTION.
IARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work). Available at: https://monographs.iarc.fr/ENG/Classification/index.php, p. V19 472
This pharmacokinetic data does not apply to povidone.
This pharmacokinetic data does not apply to povidone.
Povidone-iodine is a water-soluble complex that mediates a bactericidal or virucidal action following the gradual liberation of free iodine from the complex at the application site to react with the pathogen. Please refer to the drug entry for [DB06812] for the full mechanism of action of the complex.
Povidone-iodine is a water-soluble complex that mediates a bactericidal or virucidal action following the gradual liberation of free iodine from the complex at the application site to react with the pathogen. Please refer to the drug entry for [Povidone-iodine] for the full mechanism of action of the complex.
ONE OF MAJOR PROPERTIES OF PVP IS ITS PHYSIO-CHEMICAL BEHAVIOR, WHICH IS... COMPARABLE TO THAT OF SERUM ALBUMEN... THUS IT FIXES & TRANSPORTS WATER AS WELL AS THE PRODUCTS FIXED BY SERUM ALBUMEN... IT CAN ALSO CARRY SUCH SUBSTANCES AS UREA, CREATININE, LACTOFLAVIN, COLORING MATTERS, HORMONES, & GLUCOSE.
Lefaux, R. Practical Toxicology of Plastics. Cleveland: CRC Press Inc., 1968., p. 290
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Parenteral
Fillers, Diluents & Binders
Solubilizers
Controlled & Modified Release
Co-Processed Excipients
Taste Masking
API Stability Enhancers
Topical
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Market Place
REF. STANDARDS & IMPURITIES
USP
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
